Theme: Measurable Residual Disease (MRD) Monitoring in AML Options A. qPCR for NPM1 mutation B. qPCR for RUNX1::RUNX1T1 C. qPCR for CBFB::MYH11 D. qPCR for PML::RARA E. Multiparameter flow cytometry (MFC) F. FLT3-ITD ultra-high sensitivity NGS G. Bone marrow (BM) preferred over peripheral blood (PB) H. Peripheral blood (PB) acceptable if blasts ≥20% I. MRD monitoring not routinely recommended after 2 cycles J. Post-allogeneic transplant MRD surveillance Questions 1. A 42-year

Options A. Acute portal vein thrombosis B. Chronic portal vein thrombosis with portal cavernoma C. Budd–Chiari syndrome D. Acute mesenteric vein thrombosis E. Splenic vein thrombosis F. Myeloproliferative neoplasm-associated SVT G. Paroxysmal nocturnal haemoglobinuria (PNH) H. Cirrhosis-associated portal vein thrombosis I. Antiphospholipid syndrome-associated SVT J. Intestinal infarction secondary to SVT K. JAK2 V617F mutation-associated SVT L. Factor V Leiden-associated SVT

Option List A. Brentuximab vedotin monotherapy B. Brentuximab vedotin + bendamustine C. Brentuximab vedotin + nivolumab D. Brentuximab vedotin maintenance post-ASCT E. GDP chemotherapy F. High-dose therapy with autologous stem cell transplantation (ASCT) G. Immediate allogeneic stem cell transplantation H. Nivolumab monotherapy I. Observation only J. Pembrolizumab-GVD K. Peripheral neuropathy is a major toxicity of BV maintenance L. PET-negative status before ASCT predicts su

Theme: Investigation and Management of Antiphospholipid Syndrome (APS) Options A. Triple-positive antiphospholipid syndrome B. Catastrophic antiphospholipid syndrome (CAPS) C. Direct oral anticoagulant interference causing false-positive lupus anticoagulant D. Warfarin with target INR 2.0–3.0 E. Warfarin with target INR 3.0–4.0 F. Dual antiplatelet therapy G. Repeat antiphospholipid antibody testing after ≥12 weeks H. Lupus anticoagulant testing should be deferred I....

OPTIONS A. Hydroxyurea B. Azacitidine C. Decitabine + venetoclax D. Allogeneic stem cell transplantation E. Ruxolitinib F. Watch and wait G. Erythropoietin-stimulating agent H. Tagraxofusp I. Acute monocytic AML J. Oligomonocytic CMML K. CMML-1, dysplastic type L. CMML-2, proliferative type M. Reactive monocytosis N. VEXAS syndrome-associated CMML O. CPSSmol high-risk disease P. SF3B1-mutated CMML with ring sideroblasts Q. Therapy-related CMML R. HMA failure with clonal evolu

Theme: Acute Myeloid Leukaemia (AML) Options A. DA 3+7 plus Gemtuzumab Ozogamicin (GO) B. DA 3+10 plus Midostaurin C. CPX-351 (Vyxeos) D. FLAG-IDA E. ATRA + Arsenic Trioxide F. ATRA + Idarubicin (AIDA) G. Allogeneic stem cell transplantation in CR1 H. Gilteritinib I. Quizartinib J. Azacitidine + Donor Lymphocyte Infusion (DLI) K. HiDAC consolidation alone L. Hydroxycarbamide cytoreduction followed by induction M. Supportive/palliative management N. Enasidenib O. Ivosidenib Qu

Theme: Diagnosis, Risk Stratification and Management of ET Options A. Reactive thrombocytosis secondary to iron deficiency B. Triple-negative ET C. CALR-mutated ET D. JAK2 V617F-positive ET E. MPL-mutated ET F. Hydroxycarbamide G. Pegylated interferon-alpha H. Anagrelide I. Aspirin alone with observation J. Bone marrow biopsy and extended molecular testing K. Busulfan L. Essential thrombocythaemia in pregnancy requiring LMWH and interferon M. Idiopathic thrombocytosis of unde

Theme: ACS in SCD Options A. Immediate simple (top-up) transfusion B. Urgent red cell exchange transfusion C. Incentive spirometry and aggressive analgesia only D. Broad-spectrum antibiotics including atypical cover E. Transfer to intensive care for ventilatory support F. Pulmonary embolism should be considered and investigated G. Rib infarction leading to hypoventilation H. Fluid overload causing worsening hypoxia I. Delayed haemolytic transfusion reaction J. Hydroxycarbamid

Options A. No transfusion required B. Simple transfusion (top up) C. Exchange transfusion D. Either simple or exchange transfusion depending on severity E. Avoid transfusion unless life-threatening anaemia F. Urgent red cell exchange within hours G. Chronic transfusion programme H. Emergency transfusion followed by ICU support I. Supportive management only J. Pre-operative transfusion optimisation K. Automated exchange transfusion L. Manual exchange transfusion M. Transfusion

Theme: TLS Options Each option may be used once, more than once, or not at all. A. Oral allopurinol (standard dose) B. High-dose allopurinol (up to 800 mg/day) C. Febuxostat D. Aggressive IV hydration alone E. Fixed-dose rasburicase (3 mg stat) F. Weight-based rasburicase (0.2 mg/kg daily) G. Stop allopurinol and commence rasburicase H. Continue allopurinol and add rasburicase I. Emergency hyperkalaemia protocol J. IV calcium gluconate K. Withhold calcium replacement L. Initi

Theme: Cytogenetics & Molecular Abnormalities Options (Each option may be used once, more than once, or not at all) A. t(8;21) – RUNX1-RUNX1T1 B. inv(16) / t(16;16) – CBFB-MYH11 C. t(15;17) – PML-RARA D. t(9;22) – BCR-ABL1 E. t(11;14) – CCND1-IGH F. t(14;18) – IGH-BCL2 G. t(8;14) – MYC-IGH H. t(11;17) – PLZF-RARA I. t(5;14) – IL3-IGH J. t(4;14) – FGFR3-MMSET 📘 Questions Q1 A 32-year-old woman presents with fatigue, bruising, and gum bleeding. Blood film shows abnormal promye